MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-100038-PIP01-21-M01

Scope of the Application

Active Substance(s)

SARS CoV2 prefusion Spike delta TM (CoV2 preS dTM) protein, recombinant adjuvanted with AS03

Condition(s)

Prevention of coronavirus disease 2019 (Covid-19)

Pharmaceutical Form(s)

Solution and emulsion for emulsion for injection

Route(s) of Administration

Intramuscular use

Name / Corporate name of the PIP applicant

Sanofi Pasteur

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Sanofi Pasteur submitted to the licensing authority on 12/12/2021 23:40 GMT an application for a Modification

The procedure started on 22/12/2021 12:22 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100038-PIP01-21-M01

Of 31/01/2022 09:25 GMT

On the adopted decision for SARS CoV2 prefusion Spike delta TM (CoV2 preS dTM) protein, recombinant adjuvanted with AS03 (MHRA-100038-PIP01-21-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for SARS CoV2 prefusion Spike delta TM (CoV2 preS dTM) protein, recombinant adjuvanted with AS03, Solution and Emulsion for emulsion for injection , Intramuscular use .

This decision is addressed to Sanofi Pasteur, 14 Espace Henry Vallée , Lyon, France, 69007

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Prevention of Coronavirus disease 2019 (COVID-19)

2.2 Indication(s) targeted by the PIP:

Prevention of Coronavirus disease 2019 (COVID-19)

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Solution and Emulsion for Emulsion for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable
Non-Clinical Studies	0	Not applicable
Clinical Studies	2	Study 1 (VAT00003) Randomised, modified double-blind, controlled immunogenicity and safety Phase II/ III trial of CoV-2 preS dTM vaccine versus active vaccine comparator or placebo in children from birth to less than 18 years Study 2 (VAT00009) Open label, noncomparative, safety and immunogenicity study of CoV-2 preS dTM-AS03 vaccine in immunocompromised children and adolescents from birth to less than 18 years of age for prevention of COVID-19.
Extrapolation, Modeling & Simulation Studies	0	Not applicable
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/03/2025
Deferral of one or more studies contained in the paediatric investigation plan:	Yes